Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Gets NY State Clinical Lab Permit, Approval to Offer Genetic Tests

NEW YORK — Fulgent Genetics said on Thursday that it has received a clinical laboratory permit and approval from the New York State Department of Health (NYSDOH) to offer its next-generation sequencing tests. 

Fulgent sells genetic tests for a range of diseases and disorders, as well as custom panels for over 18,000 genes. The Temple City, California-based company also offers sequencing services for clinical and research applications.

Fulgent said it has received a NYSDOH molecular genetic testing permit, enabling it to sell its tests and services in New York state.

"The state of New York is a large and untapped market for us, and we look forward to the opportunity to improve patient care with actionable genetic testing solutions for individuals across the state," Fulgent CSO Harry Gao said in a statement.

Earlier this year, Fulgent partnered with the Precision Genomics Laboratory and the department of obstetrics and gynecology at Columbia University Irving Medical Center to offer on-site, expanded carrier screening to patients at the New York City-based academic medical center.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.